Skip to main content

Table 2 Concentrations of circulating biomarkers in patients with sinus rhythm or with atrial fibrillation recorded by ECG during scheduled visits at 6 and 12 months

From: Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation

Biomarker

Visit

Rhythm

n

Median

IQR

AUC

95%CI

Pfdr

Total NT-proBNP

(pg/mL)

6 months

Sinus

280

865

[484–1720]

0.777

(0.682–0.871)

6.1 × 10–6

AF

34

2532

[1504–4692]

12 months

Sinus

268

878

[476–1809]

0.772

(0.705–0.838)

3.0 × 10–7

AF

45

2241

[1381–4032]

NT-proBNP (pg/mL)

6 months

Sinus

284

128.0

[55.3–238.5]

0.866

(0.785–0.947)

3.3 × 10–10

AF

34

724.5

[435.8–1311.8]

12 months

Sinus

276

116.5

[54.0–242.5]

0.862

(0.806–0.918)

1.5 × 10–12

AF

45

580.0

[306.0–1180.0]

Ang2

(ng/mL)

6 months

Sinus

284

2.44

[1.95–3.03]

0.726

(0.636–8.16)

0.001

AF

34

3.27

[2.38–4.95]

12 months

Sinus

274

2.39

[1.94–3.07]

0.816

(0.754–0.877)

8.8 × 10–10

AF

45

3.75

[2.96–5.18]

BMP10

(ng/mL)

6 months

Sinus

281

1.97

[1.72–2.23]

0.710

(0.611–0.810)

2.8 × 10–4

AF

33

2.31

[2.04–2.67]

12 months

Sinus

273

1.97

[1.73–2.27]

0.634

(0.537–0.731)

0.007

AF

44

2.18

[1.91–2.65]

DKK3

(ng/mL)

6 months

Sinus

280

55.25

[47.27–63.06]

0.640

(0.541–0.738)

0.013

AF

34

59.94

[53.64–78.79]

12 months

Sinus

269

46.45

[48.20–64.09]

0.648

(0.558–0.737)

0.002

AF

45

62.66

[53.99–77.87]

ESM1

(ng/mL)

6 months

Sinus

280

1.92

[1.61–2.31]

0.601

(0.490–713)

0.067

AF

34

2.07

[1.71–2.88]

12 months

Sinus

269

1.96

[1.61–2.38]

0.623

(0.532–0.714)

0.013

AF

45

2.27

[1.87–2.80]

FABP3 (ng/mL)

6 months

Sinus

281

30.86

[25.62–38.45]

0.597

(0.495–0.699)

0.079

AF

33

33.74

[26.86–44.43

12 months

Sinus

273

33.11

[26.50–40.47]

0.457

(0.359–0.554)

0.380

AF

44

30.37

[24.61–39.34]

FGF23 (ng/mL)

6 months

Sinus

281

0.11

[0.09–0.14]

0.716

(0.625–0.807)

0.001

AF

33

0.15

[0.12–0.19]

12 months

Sinus

270

0.11

[0.09–0.15]

0.617

(0.525–0.708)

0.019

AF

44

0.14

[0.10–0.18]

GDF15 (pg/mL)

6 months

Sinus

281

1058

[791–1446]

0.602

(0.493–0.712)

0.067

AF

33

1440

[883–1715]

12 months

Sinus

273

1140

[812–1554]

0.508

(0.416–0.599)

0.870

AF

44

1143

[796–1598]

IGFBP7 (ng/mL)

6 months

Sinus

284

167.94

[153.8–186.8]

0.665

(0.564–0.766)

0.004

AF

34

187.07

[164.6–230.4]

12 months

Sinus

274

172.41

[156.0–196.7]

0.542

(0.450–0.634)

0.380

AF

45

174.74

[159.8–210.4]

MYBPC3 (pg/mL)

6 months

Sinus

281

3.09

[1.95–5.17]

0.656

(0.559–0.753)

0.006

AF

33

4.62

[2.63–9.87]

12 months

Sinus

273

2.98

[1.79–5.28]

0.609

(0.524–0.695)

0.028

AF

44

4.00

[2.48–6.68]

  1. Biomarker concentration at 6 and 12 months and results of ROC-analysis for discriminatory value to predict AF. P value from multiple testing by means of FDR-correction. NT-proBNP—N-terminal pro-B type natriuretic peptide; Ang2—angiopoietin 2; BMP10—bone morphogenic protein-10; DKK3—Dickkopf-related protein-3; ESM1—endothelial cell specific molecule 1; FABP3—fatty acid-binding protein C3; FGF23—fibroblast growth factor 23; GDF15—growth differentiation factor-15; IGFBP7—insulin like growth factor-binding protein-7; MyBPC3—myosin binding protein 3